Fresh Analyst Coverage Puts Ligand Pharmaceuticals (LGND) Royalty Model And Valuation In The Spotlight

Why fresh analyst coverage matters for Ligand Pharmaceuticals (LGND)

Recent coverage initiations from Bank of America Securities and other firms have put Ligand Pharmaceuticals (LGND) in focus, spotlighting its royalty based model, diversified portfolio and earnings outlook.

For you as an investor, this kind of attention often acts as a prompt to reassess a stock, not just on sentiment but on how its business model converts into revenue, profits and risk.

See our latest analysis for Ligand Pharmaceuticals.

Ligand Pharmaceuticals’ share price has climbed 9.11% over the past month and 7.05% over the past quarter, while its 1 year total shareholder return of 91.08% and 3 year total shareholder return of 181.19% suggest strong momentum behind the recent analyst interest.

If this kind of royalty focused model appeals to you, it could be a good moment to see what else is gaining attention in healthcare by checking our 33 healthcare AI stocks.

With shares up strongly over the past year and trading at US$202.91, while some analysts see upside toward US$244.50, the real question for you is this: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 17% Undervalued

At a last close of $202.91 versus a narrative fair value of $244.56, the most followed storyline on Ligand Pharmaceuticals argues that the current price leaves a meaningful gap, built on a specific view of its royalty pipeline, growth mix and required return of 6.98%.

Strong revenue and earnings growth are expected as Ligand broadens its high-margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late-stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long-term cash flow predictability.

Read the complete narrative.

Want to see what sits behind that cash flow confidence? The narrative leans heavily on royalty growth, margin expansion and a future earnings multiple that is far from conservative.

Result: Fair Value of $244.56 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, those royalty focused arguments can quickly unravel if drug pricing pressure bites harder than expected, or if one or two key partnered drugs underperform.

Find out about the key risks to this Ligand Pharmaceuticals narrative.

Another View: What Earnings Multiples Are Saying

Those cash flow models point to value, but the earnings multiple tells a different story. At a P/E of 32.5x versus 30.2x for peers, 17.7x for the wider US Pharmaceuticals group, and a fair ratio of 17.3x, the current price looks demanding rather than cheap. Is the royalty story strong enough to justify paying up today?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

All this points to a clear split in sentiment, so it is worth moving quickly to check the underlying data and form your own view before the story shifts again. To see what is driving the current optimism, take a look at our breakdown of 4 key rewards.

Looking for more investment ideas?

If this story has sharpened your focus, do not stop here. The next move could be finding a company that fits your style even better.

• Target long term value by checking our list of 48 high quality undervalued stocks, built from companies that score well on fundamentals and price.
• Prioritise resilience by reviewing our 68 resilient stocks with low risk scores, highlighting businesses with lower overall risk profiles.
• Spot early stage potential by scanning our screener containing 26 high quality undiscovered gems, where smaller names with solid numbers often get overlooked.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com